The U of Nebraska recently started a clinical trial to evaluate Gilead's Remdesivir to treat COVID-19, sponsored by the National Institutes of Health (NIH/NIAID).
However, it has not proven to be beneficial yet:
"“We urgently need a safe and effective treatment for COVID-19. Although Remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes,” said NIAID Director and U.S. Coronavirus Task Force member Anthony S. Fauci, M.D."
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins
Contrast that with Mesoblast's statement today (excerpt):
"Remestemcel-L has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19
infection. This is supported by recently published results from an investigator-initiated clinical study conducted in
China which reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated
patients with severe COVID-19 pneumonia."
My conclusion:
1) Dr. Itescu would not release today's PR unless he is pretty sure Remestemcel-L works. I believe he is not trying to simply get on the COVID-19 cure bandwagon to gain market attention. The man is conservative.
2) Gilead's Remdesivir is unproven so far, from Anthony Fauci's statement.
Advantage Mesoblast.
- Forums
- ASX - By Stock
- Gilead vs Mesoblast
The U of Nebraska recently started a clinical trial to evaluate...
-
-
- There are more pages in this discussion • 274 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.141B |
Open | High | Low | Value | Volume |
$1.01 | $1.01 | 94.3¢ | $8.618M | 8.821M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 43508 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 34138 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 43508 | 1.000 |
1 | 15862 | 0.995 |
5 | 58523 | 0.990 |
3 | 49529 | 0.985 |
3 | 53984 | 0.980 |
Price($) | Vol. | No. |
---|---|---|
1.005 | 34138 | 2 |
1.010 | 59763 | 4 |
1.015 | 35684 | 2 |
1.020 | 77095 | 6 |
1.025 | 66956 | 6 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online